Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver

Life Sci. 2006 Jul 17;79(8):737-43. doi: 10.1016/j.lfs.2006.02.037. Epub 2006 Apr 17.

Abstract

Leucine stimulates protein synthesis by modulating the mammalian target of rapamycin (mTOR) signaling pathway. We hypothesized that promotion of the branched-chain amino acid (BCAA) catabolism might influence the leucine-induced protein synthesis. Clofibric acid (an active metabolite of clofibrate) is known to promote the BCAA catabolism by activation of branched-chain alpha-keto acid dehydrogenase complex (BCKDC), the rate-limiting enzyme of the BCAA catabolism. In the present study, we examined the phosphorylation state of mTOR, eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), and ribosomal protein S6 kinase 1 (S6K1) in liver of rats with or without activation of the BCKDC by clofibrate treatment. Clofibrate-treated rats were prepared by oral administration of clofibrate 5 h before sacrifice. In order to stimulate phosphorylation of components in the mTOR signaling pathway, rats were orally administered with leucine 1 h before sacrifice. Clofibrate treatment almost fully activated hepatic BCKDC and significantly decreased the plasma leucine concentration in rats without leucine administration, resulting in decreased mTOR and 4E-BP1 phosphorylation. Similarly, in rats administered with leucine, clofibrate treatment attenuated the predicted increase in plasma leucine concentration as well as the phosphorylation of mTOR, 4E-BP1, and S6K1. These results suggest that BCAA catabolism enhanced by clofibrate treatment has significant influences on the leucine-induced activation of translation initiation processes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) / metabolism*
  • Amino Acids, Branched-Chain / metabolism*
  • Animals
  • Carrier Proteins / metabolism
  • Clofibrate / administration & dosage
  • Clofibrate / pharmacology*
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / pharmacology*
  • Intracellular Signaling Peptides and Proteins
  • Leucine / administration & dosage
  • Liver / drug effects*
  • Liver / metabolism*
  • Male
  • Multienzyme Complexes / metabolism
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Protein Kinases / metabolism*
  • Rats
  • Ribosomal Protein S6 Kinases, 90-kDa / metabolism
  • TOR Serine-Threonine Kinases

Substances

  • Amino Acids, Branched-Chain
  • Carrier Proteins
  • Eif4ebp1 protein, rat
  • Hypolipidemic Agents
  • Intracellular Signaling Peptides and Proteins
  • Multienzyme Complexes
  • Phosphoproteins
  • 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
  • Protein Kinases
  • mTOR protein, rat
  • Ribosomal Protein S6 Kinases, 90-kDa
  • Rps6ka1 protein, rat
  • TOR Serine-Threonine Kinases
  • (3-methyl-2-oxobutanoate dehydrogenase (lipoamide)) kinase
  • Leucine
  • Clofibrate